ClinicalTrials.gg
CompletedNCT02932904Updated Sep 14, 2018Results posted

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

A Phase 4 interventional study of Vortioxetine and Paroxetine in Healthy Volunteers, sponsored by Takeda. Completed at 15 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-14.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of vortioxetine (10 and 20 mg, once daily) versus paroxetine (20 mg, once daily) on sexual functioning in healthy participants after 5 weeks of double-blind treatment.

Read the detailed description

The drug being tested in this study is called vortioxetine. This study will look at the effect of treatment on sexual functioning in healthy participants.

The study will enroll approximately 352 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Vortioxetine 10 mg
  • Vortioxetine 20 mg
  • Paroxetine 20 mg
  • Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient

All participants will be asked to take one tablet/capsule, daily, orally for up to 5 weeks.

This multicenter trial will be conducted in United States. The overall time to participate in this study is approximately 7 weeks. Participants will be contacted by telephone 2 weeks after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is sexually active and has been in a steady relationship and plans to remain in that relationship for the duration of the study.
  2. Has a (BMI) of 18 to 35 kg/m\^2, inclusive, at the Screening and Baseline Visits.
  3. If female, has a regular menstrual cycle.
  4. Has normal sexual functioning, as defined by a Changes in Sexual Functioning Questionnaire (CSFQ-14) total score >47 (men) or >41 (women) at the Screening and Baseline Visits.
  5. If females, taking allowed hormonal is on a stable dose for ≥3 months prior to the Baseline Visit and continues on the stable dose for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Has received vortioxetine and/or paroxetine in a previous clinical study or as a therapeutic agent.
  2. Is positive for surface antigen (HBsAg), anti- virus (HCV) antibodies, or (HIV) at the Screening Visit or has any known sexually transmitted diseases.
  3. Has glycosylated () ≥7% at the Screening Visit.
  4. Has a abnormal (ECG) at the Screening Visit.
  5. Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  6. Has a history of depression or any other psychiatric illness.
  7. Has a significant risk of suicide according to the investigator's clinical judgment, or has made a suicide attempt in the previous 6 months.
  8. Has current sexual dysfunction, or a history of a diagnosis or treatment of sexual dysfunction.
  9. Has had a surgical or medical procedure on reproductive/genitourinary organs (excluding uncomplicated vasectomy and tubal ligation).
  10. If female, has polycystic ovarian syndrome.
  11. Has hypogonadism or has a free testosterone value outside the normal range at the Screening Visit that is indicative of hypogonadism.
  12. Has a thyroid-stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 20 mg

    Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.

    Drug: Vortioxetine

  • Active comparator
    Paroxetine 20 mg

    Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.

    Drug: Paroxetine

  • Placebo comparator
    Placebo

    Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.

    Drug: Placebo

Interventions

  • Vortioxetine Overencapsulated Tablet

  • Paroxetine Overencapsulated Tablets.

  • DrugPlacebo

    Vortioxetine Placebo-matching Capsules.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Week 5

  2. Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Week 5

  3. Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Week 5

Secondary outcomes

  1. Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Weeks 1, 2, 3 and 4

  2. Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Weeks 1, 2, 3, 4 and 5

  3. Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Weeks 1, 2, 3, 4 and 5

  4. Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5

    Sexual dysfunction is defined as CSFQ-14 score ≤47 for men and ≤41 for women.

    Time frame: Weeks 1, 2, 3, 4 and 5

  5. Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the subscales of pleasure (1 item, score range 1-5), desire/frequency (2 items, score range 2-10), desire/interest (3 items, score range 3-15), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Weeks 1, 2, 3, 4 and 5

  6. Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5

    The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the 3 phases of the sexual response cycle , desire (5 items, score range 5-25), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

    Time frame: Baseline and Weeks 1, 2, 3, 4 and 5

07

Results

Posted Sep 14, 2018

Participant flow

Participants took part in the study at 16 investigative sites in the United States from 21 November 2016 to 09 June 2017.

Participant flow — Overall Study
MilestonePlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Started92859193
Treated91849191
Completed76676879
Not completed16182314
Withdrew: Reason not specified1022
Withdrew: Noncompliance with study drug2334
Withdrew: Pregnancy0110
Withdrew: Study termination0100
Withdrew: Voluntary withdrawal2142
Withdrew: Lost to follow-up5360
Withdrew: Significant protocol deviation2361
Withdrew: Pretreatment event/adverse event3513
Withdrew: Randomized but not treated1102

Outcome measures

PrimaryChange From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)
score on a scaleParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Baseline59.27 ± 0.58458.56 ± 0.57859.43 ± 0.560
Change from Baseline at Week 5-3.56 ± 0.758-0.82 ± 0.752-2.51 ± 0.727
Statistical analysis
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.009 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Least square (ls) mean difference: 2.74 · 95% CI 0.69 to 4.78
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.303 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Ls mean difference: 1.05 · 95% CI -0.95 to 3.05
SecondaryChange From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Weeks 1, 2, 3 and 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4
score on a scaleParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Week 1-1.67 ± 0.457-0.54 ± 0.453-0.38 ± 0.436
Week 2-2.40 ± 0.617-1.18 ± 0.612-1.55 ± 0.592
Week 3-2.77 ± 0.661-0.77 ± 0.655-2.36 ± 0.633
Week 4-3.11 ± 0.688-1.20 ± 0.683-2.43 ± 0.659
Statistical analysis
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.072 · Ls mean difference: 1.13 · 95% CI -0.10 to 2.37
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.035 · Ls mean difference: 1.29 · 95% CI 0.09 to 2.50
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.149 · Ls mean difference: 1.22 · 95% CI -0.44 to 2.89
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.303 · Ls mean difference: 0.85 · 95% CI -0.78 to 2.48
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.028 · Ls mean difference: 2.00 · 95% CI 0.22 to 3.78
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.645 · Ls mean difference: 0.41 · 95% CI -1.33 to 2.15
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.043 · Ls mean difference: 1.91 · 95% CI 0.06 to 3.77
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.465 · Ls mean difference: 0.68 · 95% CI -1.14 to 2.49
SecondaryChange From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Weeks 1, 2, 3, 4 and 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
score on a scalePlaceboParoxetine 20 mg
Week 1-0.05 ± 0.440-1.67 ± 0.457
Week 2-1.11 ± 0.598-2.40 ± 0.617
Week 3-0.91 ± 0.639-2.77 ± 0.661
Week 4-0.62 ± 0.666-3.11 ± 0.688
Week 5-0.79 ± 0.734-3.56 ± 0.758
Statistical analysis
  • Placebo vs Paroxetine 20 mg · ANCOVA with LOCF · p = 0.009 · Ls mean difference: -1.63 · 95% CI -2.84 to -0.41
  • Placebo vs Paroxetine 20 mg · ANCOVA with LOCF · p = 0.123 · Ls mean difference: -1.29 · 95% CI -2.93 to 0.35
  • Placebo vs Paroxetine 20 mg · ANCOVA with LOCF · p = 0.039 · Ls mean difference: -1.85 · 95% CI -3.61 to -0.10
  • Placebo vs Paroxetine 20 mg · ANCOVA with LOCF · p = 0.008 · Ls mean difference: -2.49 · 95% CI -4.32 to -0.66
  • Placebo vs Paroxetine 20 mg · ANCOVA with LOCF · p = 0.007 · Ls mean difference: -2.77 · 95% CI -4.78 to -0.75
SecondaryChange From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Weeks 1, 2, 3, 4 and 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
score on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Week 1-0.05 ± 0.440-0.54 ± 0.453-0.38 ± 0.436
Week 2-1.11 ± 0.598-1.18 ± 0.612-1.55 ± 0.592
Week 3-0.91 ± 0.639-0.77 ± 0.655-2.36 ± 0.633
Week 4-0.62 ± 0.666-1.20 ± 0.683-2.43 ± 0.659
Week 5-0.79 ± 0.734-0.82 ± 0.752-2.51 ± 0.727
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.419 · Ls mean difference: -0.50 · 95% CI -1.70 to 0.71
  • Placebo vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.581 · Ls mean difference: -0.33 · 95% CI -1.51 to 0.85
  • Placebo vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.938 · Ls mean difference: -0.06 · 95% CI -1.69 to 1.56
  • Placebo vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.592 · Ls mean difference: -0.44 · 95% CI -2.04 to 1.17
  • Placebo vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.870 · Ls mean difference: 0.15 · 95% CI -1.60 to 1.89
  • Placebo vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.098 · Ls mean difference: -1.44 · 95% CI -3.16 to 0.27
  • Placebo vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.532 · Ls mean difference: -0.58 · 95% CI -2.39 to 1.24
  • Placebo vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.046 · Ls mean difference: -1.82 · 95% CI -3.60 to -0.03
  • Placebo vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.977 · Ls mean difference: -0.03 · 95% CI -2.03 to 1.97
  • Placebo vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.087 · Ls mean difference: -1.72 · 95% CI -3.68 to 0.25
SecondaryPercentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5

Sexual dysfunction is defined as CSFQ-14 score ≤47 for men and ≤41 for women.

Time frame:
Weeks 1, 2, 3, 4 and 5
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5
percentage of participantsPlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Week 12.22.41.21.1
Week 27.98.43.52.2
Week 34.58.43.56.6
Week 44.59.64.77.7
Week 53.49.65.99.9
Statistical analysis
  • Paroxetine 20 mg vs Vortioxetine 10 mg · Regression, Logistic · p = 0.515 · Odds ratio (or): 0.44 · 95% CI 0.037 to 5.201
  • Paroxetine 20 mg vs Vortioxetine 20 mg · Regression, Logistic · p = 0.677 · Odds ratio (or): 0.59 · 95% CI 0.049 to 7.051
  • Placebo vs Paroxetine 20 mg · Regression, Logistic · p = 0.720 · Odds ratio (or): 1.47 · 95% CI 0.181 to 11.912
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.732 · Odds ratio (or): 0.65 · 95% CI 0.053 to 7.861
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.913 · Odds ratio (or): 0.87 · 95% CI 0.066 to 11.303
  • Paroxetine 20 mg vs Vortioxetine 10 mg · Regression, Logistic · p = 0.164 · Odds ratio (or): 0.37 · 95% CI 0.090 to 1.507
  • Paroxetine 20 mg vs Vortioxetine 20 mg · Regression, Logistic · p = 0.098 · Odds ratio (or): 0.25 · 95% CI 0.050 to 1.287
  • Placebo vs Paroxetine 20 mg · Regression, Logistic · p = 0.758 · Odds ratio (or): 1.20 · 95% CI 0.383 to 3.731
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.256 · Odds ratio (or): 0.44 · 95% CI 0.107 to 1.814
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.154 · Odds ratio (or): 0.30 · 95% CI 0.059 to 1.561
  • Paroxetine 20 mg vs Vortioxetine 10 mg · Regression, Logistic · p = 0.160 · Odds ratio (or): 0.36 · 95% CI 0.087 to 1.497
  • Paroxetine 20 mg vs Vortioxetine 20 mg · Regression, Logistic · p = 0.744 · Odds ratio (or): 0.82 · 95% CI 0.252 to 2.679
  • Placebo vs Paroxetine 20 mg · Regression, Logistic · p = 0.194 · Odds ratio (or): 2.43 · 95% CI 0.636 to 9.317
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.871 · Odds ratio (or): 0.88 · 95% CI 0.181 to 4.261
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.329 · Odds ratio (or): 2.00 · 95% CI 0.497 to 8.037
  • Paroxetine 20 mg vs Vortioxetine 10 mg · Regression, Logistic · p = 0.187 · Odds ratio (or): 0.42 · 95% CI 0.119 to 1.514
  • Paroxetine 20 mg vs Vortioxetine 20 mg · Regression, Logistic · p = 0.729 · Odds ratio (or): 0.82 · 95% CI 0.273 to 2.476
  • Placebo vs Paroxetine 20 mg · Regression, Logistic · p = 0.133 · Odds ratio (or): 2.71 · 95% CI 0.739 to 9.917
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.852 · Odds ratio (or): 1.15 · 95% CI 0.266 to 4.961
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.240 · Odds ratio (or): 2.23 · 95% CI 0.585 to 8.472
  • Paroxetine 20 mg vs Vortioxetine 10 mg · Regression, Logistic · p = 0.317 · Odds ratio (or): 0.55 · 95% CI 0.166 to 1.789
  • Paroxetine 20 mg vs Vortioxetine 20 mg · Regression, Logistic · p = 0.790 · Odds ratio (or): 1.15 · 95% CI 0.410 to 3.233
  • Placebo vs Paroxetine 20 mg · Regression, Logistic · p = 0.073 · Odds ratio (or): 3.64 · 95% CI 0.888 to 14.911
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.371 · Odds ratio (or): 1.98 · 95% CI 0.442 to 8.902
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = 0.046 · Odds ratio (or): 4.19 · 95% CI 1.027 to 17.063
SecondaryChange From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the subscales of pleasure (1 item, score range 1-5), desire/frequency (2 items, score range 2-10), desire/interest (3 items, score range 3-15), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Weeks 1, 2, 3, 4 and 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5
score on a scalePlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Pleasure Score: Week 1-0.07 ± 0.064-0.36 ± 0.066-0.13 ± 0.065-0.15 ± 0.063
Pleasure Score: Week 2-0.26 ± 0.079-0.38 ± 0.082-0.25 ± 0.081-0.26 ± 0.078
Pleasure Score: Week 3-0.23 ± 0.085-0.44 ± 0.088-0.18 ± 0.087-0.42 ± 0.084
Pleasure Score: Week 4-0.18 ± 0.085-0.38 ± 0.088-0.31 ± 0.087-0.37 ± 0.084
Pleasure Score: Week 5-0.21 ± 0.086-0.47 ± 0.089-0.16 ± 0.088-0.33 ± 0.085
Desire/Frequency Score: Week 1-0.03 ± 0.097-0.35 ± 0.100-0.07 ± 0.099-0.23 ± 0.096
Desire/Frequency Score: Week 2-0.30 ± 0.118-0.46 ± 0.122-0.25 ± 0.120-0.46 ± 0.116
Desire/Frequency Score: Week 3-0.33 ± 0.128-0.62 ± 0.132-0.23 ± 0.131-0.50 ± 0.127
Desire/Frequency Score: Week 4-0.25 ± 0.126-0.55 ± 0.130-0.20 ± 0.129-0.43 ± 0.125
Desire/Frequency Score: Week 5-0.28 ± 0.141-0.66 ± 0.145-0.15 ± 0.144-0.49 ± 0.139
Desire/Interest Score: Week 10.12 ± 0.162-0.15 ± 0.169-0.16 ± 0.1670.09 ± 0.161
Desire/Interest Score: Week 2-0.09 ± 0.181-0.38 ± 0.186-0.11 ± 0.185-0.22 ± 0.179
Desire/Interest Score: Week 3-0.16 ± 0.193-0.47 ± 0.200-0.01 ± 0.198-0.28 ± 0.191
Desire/Interest Score: Week 4-0.11 ± 0.200-0.52 ± 0.206-0.18 ± 0.204-0.35 ± 0.198
Desire/Interest Score: Week 5-0.14 ± 0.215-0.73 ± 0.223-0.05 ± 0.221-0.33 ± 0.213
Arousal/Excitement/Erection Score: Week 1-0.01 ± 0.136-0.30 ± 0.141-0.05 ± 0.140-0.03 ± 0.135
Arousal/Excitement/Erection Score: Week 2-0.34 ± 0.175-0.47 ± 0.181-0.35 ± 0.179-0.30 ± 0.174
Arousal/Excitement/Erection Score: Week 3-0.22 ± 0.182-0.43 ± 0.188-0.08 ± 0.186-0.51 ± 0.180
Arousal/Excitement/Erection Score: Week 4-0.11 ± 0.181-0.54 ± 0.187-0.10 ± 0.185-0.54 ± 0.179
Arousal/Excitement/Erection Score: Week 5-0.19 ± 0.195-0.67 ± 0.202-0.03 ± 0.200-0.54 ± 0.193
Orgasm/Completion/Ejaculation Score: Week 1-0.12 ± 0.130-0.48 ± 0.135-0.22 ± 0.134-0.15 ± 0.129
Orgasm/Completion/Ejaculation Score: Week 2-0.21 ± 0.158-0.61 ± 0.164-0.26 ± 0.162-0.37 ± 0.157
Orgasm/Completion/Ejaculation Score: Week 3-0.20 ± 0.176-0.75 ± 0.183-0.33 ± 0.180-0.67 ± 0.175
Orgasm/Completion/Ejaculation Score: Week 4-0.14 ± 0.194-1.04 ± 0.201-0.45 ± 0.199-0.72 ± 0.192
Orgasm/Completion/Ejaculation Score: Week 5-0.12 ± 0.206-1.09 ± 0.214-0.42 ± 0.211-0.79 ± 0.204
SecondaryChange From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the 3 phases of the sexual response cycle , desire (5 items, score range 5-25), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Weeks 1, 2, 3, 4 and 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5
score on a scalePlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Desire Score: Week 10.09 ± 0.225-0.50 ± 0.234-0.23 ± 0.232-0.14 ± 0.223
Desire Score: Week 2-0.40 ± 0.260-0.83 ± 0.269-0.34 ± 0.266-0.68 ± 0.258
Desire Score: Week 3-0.50 ± 0.286-1.09 ± 0.296-0.22 ± 0.293-0.77 ± 0.284
Desire Score: Week 4-0.36 ± 0.297-1.07 ± 0.307-0.37 ± 0.304-0.77 ± 0.294
Desire Score: Week 5-0.42 ± 0.325-1.38 ± 0.336-0.19 ± 0.333-0.82 ± 0.322
Arousal Score: Week 1-0.01 ± 0.136-0.30 ± 0.141-0.05 ± 0.140-0.03 ± 0.135
Arousal Score: Week 2-0.34 ± 0.175-0.47 ± 0.181-0.35 ± 0.179-0.30 ± 0.174
Arousal Score: Week 3-0.22 ± 0.182-0.43 ± 0.188-0.08 ± 0.186-0.51 ± 0.180
Arousal Score: Week 4-0.11 ± 0.181-0.54 ± 0.187-0.10 ± 0.185-0.54 ± 0.179
Arousal Score: Week 5-0.19 ± 0.195-0.67 ± 0.202-0.03 ± 0.200-0.54 ± 0.193
Orgasm/Completion/Ejaculation Score: Week 1-0.12 ± 0.130-0.48 ± 0.135-0.22 ± 0.134-0.15 ± 0.129
Orgasm/Completion/Ejaculation Score: Week 2-0.21 ± 0.158-0.61 ± 0.164-0.26 ± 0.162-0.37 ± 0.157
Orgasm/Completion/Ejaculation Score: Week 3-0.20 ± 0.176-0.75 ± 0.183-0.33 ± 0.180-0.67 ± 0.175
Orgasm/Completion/Ejaculation Score: Week 4-0.14 ± 0.194-1.04 ± 0.201-0.45 ± 0.199-0.72 ± 0.192
Orgasm/Completion/Ejaculation Score: Week 5-0.12 ± 0.206-1.09 ± 0.214-0.42 ± 0.211-0.79 ± 0.204
PrimaryChange From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)
score on a scaleParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Baseline59.13 ± 0.61458.55 ± 0.58259.36 ± 0.576
Change from Baseline at Week 5-4.01 ± 0.803-0.63 ± 0.763-2.38 ± 0.754
Statistical analysis
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = 0.002 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Ls mean difference: 3.38 · 95% CI 1.25 to 5.51
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.129 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Ls mean difference: 1.63 · 95% CI -0.47 to 3.73
PrimaryChange From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)

The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)
score on a scaleParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
Baseline58.73 ± 0.67558.53 ± 0.58959.23 ± 0.591
Change from Baseline at Week 5-4.78 ± 0.828-0.47 ± 0.724-1.72 ± 0.724
Statistical analysis
  • Paroxetine 20 mg vs Vortioxetine 10 mg · ANCOVA with LOCF · p = <0.001 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Ls mean difference: 4.31 · 95% CI 2.19 to 6.43
  • Paroxetine 20 mg vs Vortioxetine 20 mg · ANCOVA with LOCF · p = 0.005 (The comparisons were between each vortioxetine dose (10 or 20 mg) and paroxetine, and the Holm-Bonferroni method was used to adjust for multiplicity and control the familywise type I error rate at a significance level of 0.05.) · Ls mean difference: 3.06 · 95% CI 0.95 to 5.17

Adverse events

Collected over From the first dose of study drug on Day 1 until the Follow-up Contact at Week 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/91 (0%)0/91 (0%)36/91 (39.6%)
Paroxetine 20 mg0/84 (0%)0/84 (0%)59/84 (70.2%)
Vortioxetine 10 mg0/91 (0%)0/91 (0%)52/91 (57.1%)
Vortioxetine 20 mg0/91 (0%)0/91 (0%)40/91 (44%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mg
NauseaGastrointestinal disorders4/9122/8426/9118/91
Libido decreasedPsychiatric disorders11/9118/8414/9110/91
Orgasm abnormalPsychiatric disorders2/9114/847/913/91
SomnolenceNervous system disorders4/9110/847/917/91
Decreased appetiteMetabolism and nutrition disorders1/916/844/911/91
HeadacheNervous system disorders6/916/842/916/91
DizzinessNervous system disorders1/916/840/911/91
AnxietyPsychiatric disorders1/916/841/911/91
InsomniaPsychiatric disorders0/916/841/911/91
DiarrhoeaGastrointestinal disorders3/915/841/913/91

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean27.8 ± 5.4528.9 ± 5.9628.1 ± 5.5628.8 ± 5.9128.4 ± 5.72
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Female46424444176
Male46434749185
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Hispanic or Latino2120251884
Non-Hispanic and Latino71656675277
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
American Indian or Alaska Native00303
Asian732315
Black or African American30293134124
Native Hawaiian or Other Pacific Islander01001
White51495255207
Multiracial433111
Region of Enrollment
Region of Enrollment(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
United States92859193361
Median Age Categories
Median Age Categories(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
≤ 28 Years51435247193
> 28 Years41423946168
Race Categories
Race Categories(Participants)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
White51495255207
Non-white41363938154
Height
Height(cm)PlaceboParoxetine 20 mgVortioxetine 10 mgVortioxetine 20 mgTotal
Mean172.0 ± 10.75172.1 ± 10.59171.3 ± 9.14170.8 ± 10.04171.5 ± 10.12

6 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Encino, California, United States
  • Long Beach, California, United States
  • Torrance, California, United States
  • Jacksonville, Florida, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • Saint Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Portland, Oregon, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Charlottesville, Virginia, United States
  • Seattle, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in May 2017, 6 months.

Results were first posted in Sep 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2016
First posted
Oct 13, 2016
StartActual
Nov 21, 2016
Primary completionActual
May 31, 2017
CompletionActual
Jun 9, 2017
Results first posted
Sep 14, 2018
Last update
Sep 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02932904
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Nov 21, 2016
Primary completion
May 31, 2017
Completion
Jun 9, 2017
Results posted
Sep 14, 2018
Last update
Sep 14, 2018

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion